Drug Development Services for Brain Tumors

Alfa Cytology provides all-sided basic research services including tumor microenvironment detection, omics analysis and cell analysis.

Alfa Cytology specializes in tumor biomarker analysis and sequencing techniques to provide advanced diagnostic services for brain tumors.

Alfa Cytology offers comprehensive services for the therapeutic development of brain tumors, including target identification, drug validation and delivery system innovation.

Alfa Cytology offers diverse brain tumor models and conducts thorough drug efficacy, pharmacokinetic and safety analyses to facilitate drug development of brain tumors.

We focused on DNA damage repair mechanisms including enzymes such as MGMT, IDH1/2 and PARPs.

We provide expertise in developing tyrosine kinase inhibitors targeting EGFRs, PI3K/AKT/mTOR pathways, MET, etc.

We concentrate on the modulators of the cell cycle with a special focus on the pRB/CDK4/RB1 and p53 pathways.

We have specialized in VEGFs and related cytokines as brain tumors are characterized by the abnormality in vascular proliferation.

Our team has been deeply engaged in the development of immune checkpoint inhibitors targeting PD-1, LAG-3, CTLA-4, IDO1, etc.

We have been dedicated to developing TAM modulators targeting MERTK, AXL and CSF-1R.

We offer cutting-edge AI-assisted screening, target identification, drug delivery system innovation and comprehensive preclinical evaluations.

Our capabilities include antibody discovery, engineering, purification, delivery and production for the purpose of advancing antibody discovery and development.

Our services for cell therapy covers immune cell isolation, culturation, genetic engineering, characterization and therapeutic efficacy evaluation.

We provide services covering plasmid vector manufacture, delivery system innovation and pharmacodynamic evaluation.

We specialize in oncolytic virotherapy and offer engineering, construction and therapeutic evaluation of oncolytic viruses both in vitro and in vivo.

We excel at early antigen discovery, small-scale manufacturing, purification and immunogenicity evaluation of tumor vaccines.